Stiripentol

Dravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Health, Pharmaceutical, FDA, Dravet syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of diseases, DST, Food, GW Pharmaceuticals, Stiripentol, Chapter Four, Chapter Five, Chapter Three, USFDA, Safety, Awareness, Geography, CAGR, Research, Ho Chi Minh City Metro (Earlier proposals), Seizure, Chapter Six, Type, Efficiency, Pharmaceutical industry, Fertilizer, Cannabidiol, Cannabidiol

The "Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dravet Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.
  • However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies.
  • Thus, overall environment of Dravet syndrome treatment market is growing significantly due to strong drug pipeline and recently approved drugs.
  • Global Dravet Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
    Chapter 4.

The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome

Retrieved on: 
Monday, December 21, 2020
Drugs, Neurological disorders, Orphan drugs, Clinical medicine, Anorectics, Epilepsy, Substituted amphetamines, Fenfluramine, Dravet syndrome, Stiripentol

With the EC approval in place, we can now begin making FINTEPLA more widely available for the treatment of Dravet syndrome patients in Europe who seek new safe and effective treatment options.

Key Points: 
  • With the EC approval in place, we can now begin making FINTEPLA more widely available for the treatment of Dravet syndrome patients in Europe who seek new safe and effective treatment options.
  • Experience from clinical studies has shown that FINTEPLA offers an impressive reduction in seizures, plus an improvement in quality of life.
  • Earlier this year, FINTEPLA was approved by the U.S. Food & Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome in patients aged two years and older.
  • These statements include the potential that fenfluramine oral solution will be an important new treatment option for Dravet syndrome patients; Zogenixs plans to commercialize fenfluramine in Europe, including the timing of the launch.

JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

Retrieved on: 
Monday, December 2, 2019
Neurological disorders, Organ systems, Health, Lennox–Gastaut syndrome, Dravet syndrome, Epilepsy, Anticonvulsant, Epileptic seizure, Stiripentol, Epilepsy-intellectual disability in females, Epilepsy syndromes

The study demonstrated that adding FINTEPLA to these patients treatment regimens led to a significant and clinically meaningful (> 50%) reduction in monthly convulsive seizure frequency (MCSF).

Key Points: 
  • The study demonstrated that adding FINTEPLA to these patients treatment regimens led to a significant and clinically meaningful (> 50%) reduction in monthly convulsive seizure frequency (MCSF).
  • Patients in the FINTEPLA arm also experienced longer seizure-free intervals, which is important as many were previously experiencing multiple seizures per week.
  • Study 1504 was an international, double-blind, placebo-controlled Phase 3 study of 87 Dravet syndrome patients age 2-19 taking background anti-epileptic drug regimens that included stiripentol, randomized to placebo (n=44) or FINTEPLA 0.4 mg/kg/day (n=43)*.
  • Zogenix expects top-line data from its Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome (LGS) in the first quarter of 2020.

US Bioservices Selected by Biocodex SAS to Exclusively Dispense DIACOMIT® (stiripentol)

Retrieved on: 
Wednesday, April 24, 2019
Health, Pharmaceutical, Children, FDA, Consumer, Neurological disorders, Chemistry, Physical sciences, Epilepsy, Dravet syndrome, Stiripentol, AmerisourceBergen, Pharmacy

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Biocodex SAS to exclusively dispense DIACOMIT (stiripentol).

Key Points: 
  • US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Biocodex SAS to exclusively dispense DIACOMIT (stiripentol).
  • DS is characterized by severe epilepsy, psychomotor retardation and a high mortality rate reported in up to 21 percent of these patients.
  • "US Bioservices is proud to partner with Biocodex to bring this innovative treatment to patients affected by Dravet syndrome, said Angela Ward, President of US Bioservices.
  • We welcome the opportunity to facilitate access to treatment and provide clinically-coordinated care for patients who are prescribed DIACOMIT.